New hope for tough blood cancers: experimental combo targets resistant leukemia
NCT ID NCT06621212
Summary
This study is testing whether a new three-drug combination can help control acute myeloid leukemia (AML) that has returned or hasn't responded to previous treatments. The trial will enroll 72 adults with relapsed or refractory AML to receive the drug combination and closely monitor their response and safety. Researchers hope this approach will reduce cancer levels and extend survival for patients who currently have limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID MALIGNANCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.